ABEO Abeona Therapeutics Inc
Price (delayed)
$4.84
Market cap
$234.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.55
Enterprise value
$234.26M
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
Highlights
The company's quick ratio rose by 47% YoY
ABEO's EPS is up by 39% year-on-year and by 31% since the previous quarter
Abeona Therapeutics's equity has surged by 197% YoY but it has decreased by 3.8% QoQ
Abeona Therapeutics's net income has decreased by 18% YoY but it has increased by 10% QoQ
The revenue has dropped by 100% year-on-year
The company's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of ABEO
Market
Valuations
Earnings
Shares outstanding
48.53M
Market cap
$234.9M
Enterprise value
$234.26M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$64.21M
Net income
-$63.73M
EBIT
-$59.53M
EBITDA
-$56.62M
Free cash flow
-$58.44M
Per share
Balance sheet
Liquidity
EPS
-$1.55
EPS diluted
-$1.55
Free cash flow per share
-$1.42
Book value per share
$1.01
Revenue per share
$0
TBVPS
$2.65
Total assets
$108.93M
Total liabilities
$64.9M
Debt
$23.05M
Equity
$44.03M
Working capital
$84.27M
Debt to equity
0.52
Current ratio
6.08
Quick ratio
6.01
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-58.2%
Return on equity
-165.4%
Return on invested capital
-63.5%
Return on capital employed
-64.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABEO stock price
How has the Abeona Therapeutics stock price performed over time
Intraday
-0.21%
1 week
15.79%
1 month
-8.68%
1 year
-38.97%
YTD
-13.11%
QTD
1.68%
Financial performance
How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$64.21M
Net income
-$63.73M
Gross margin
N/A
Net margin
N/A
The revenue has dropped by 100% year-on-year
The company's gross profit has shrunk by 100% YoY
The operating income has decreased by 41% YoY and by 6% from the previous quarter
Abeona Therapeutics's net income has decreased by 18% YoY but it has increased by 10% QoQ
Growth
What is Abeona Therapeutics's growth rate over time
Valuation
What is Abeona Therapeutics stock price valuation
P/E
N/A
P/B
4.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ABEO's EPS is up by 39% year-on-year and by 31% since the previous quarter
Abeona Therapeutics's equity has surged by 197% YoY but it has decreased by 3.8% QoQ
The price to book (P/B) is 59% higher than the 5-year quarterly average of 3.0
The revenue has dropped by 100% year-on-year
Efficiency
How efficient is Abeona Therapeutics business performance
Abeona Therapeutics's return on equity has surged by 50% YoY and by 27% QoQ
The company's return on invested capital rose by 44% YoY and by 24% QoQ
The company's return on assets rose by 36% YoY and by 19% QoQ
Dividends
What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABEO.
Financial health
How did Abeona Therapeutics financials performed over time
The company's total assets is 68% higher than its total liabilities
The company's total assets has surged by 70% YoY but it fell by 10% QoQ
The company's quick ratio rose by 47% YoY
Abeona Therapeutics's debt is 48% lower than its equity
Abeona Therapeutics's equity has surged by 197% YoY but it has decreased by 3.8% QoQ
Abeona Therapeutics's debt to equity has increased by 44% YoY and by 4% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.